Background: Tacrolimus is one of the most widely used liver transplant medications.
Introduction
With the increasing proportion and number of obese patients requiring liver transplants, 1 knowledge of the effect of obesity on factors affecting post-operative outcomes is increasingly required. Specifically, the effect of different transplant medication regimens based on an individual's body size and composition appears relevant. However, isolating the effects of one factor on outcomes can be difficult in this complex setting. Assessing efficacy and toxicity of drug dosing choices and regimens is one such occasion whereby measuring clinical outcomes are preferred. However, such studies are often expensive, have slow recruitment due to paucity of numbers and time-consuming in terms of long-term follow up. Fortunately, drug exposure through measurement of appropriately timed plasma concentrations is correlated with clinical outcomes for many transplant drugs 2-5 and has become an accepted tool to guide dosing in this setting. Therefore, plasma drug concentrations are used as a surrogate marker for therapeutic efficacy. [6] [7] [8] Tacrolimus is one of the most widely used liver transplant medications, with efficacy and toxicity correlated with drug exposure. In this work, we aimed to describe tacrolimus dose and plasma concentrations based on a sequential cohort of liver transplant patients. Specifically, we aimed to investigate (i) whether patient body size parameters affect trough plasma concentrations of tacrolimus when a standard mg/kg dosing regimen is used (dosing is based on the patient's total bodyweight) and (ii) whether obese patients have different numbers of plasma concentrations outside the therapeutic range compared to non-obese patients. Although numbers of poor outcomes are now relatively few with liver transplant in comparison to other transplanted organs, we aimed also to describe any relationship between obesity and/or plasma concentrations and elevated liver function, infection and other reported adverse events.
Methods
We undertook this single-centre retrospective study at the Princess Alexandra Hospital, Queensland, a tertiary hospital that undertakes more than 50 liver transplants per year (https://metrosouth.health.qld.gov.au/transplant). With low-risk ethics approval, medical records for patients having a liver transplant between years 2013 and 2014 were collected from 69 liver transplant recipients from the Transplant eVici database located in the Queensland Liver Transplant Service based at that hospital.
Tacrolimus (Prograf; Janssen-Cilag, Dublin, Ireland) was dosed at 0.1 mg/kg/day to start for all patients, and then adjusted to maintain a target trough concentration: 8-10 ng/mL during the first 3 months after transplant; 5-8 ng/mL between 3 and 12 months; 3-5 ng/mL after 12 months. Blood samples (i.e. trough concentrations) were collected every day from the second day after the transplant operation for 13 days continuously. For the purposes of this study, additional blood sample results at 1, 3 and 6 months post-transplant were also collected and reviewed. Blood samples were collected before dosing in the morning. The blood samples were analysed with a high-performance liquid chromatography tandem mass spectroscopy method previously published. 9 This assay is specific for the parent drug tacrolimus, is linear over the range of 0.5-50 ng/mL (r 2 > 0.99) and has a within-and between-day imprecision of less than 8%. A Pearson correlation coefficient test was applied in R to assess the correlation between the tacrolimus plasma concentrations and surrogate clinical outcomes (e.g. liver function). Student's t-test was used for calculating the P value to investigate the statistical difference between two groups.
Results
Patient demographic data are presented in Table 1 . Of the 69 patients, 20 were categorised as obese (body mass index (BMI) > 30 kg/m 2 ).
In Table 2 , median values and range of tacrolimus plasma trough concentrations at different sampling days are presented for obese and non-obese patients respectively. The trough concentrations are similar between obese and non-obese patients (P > 0.05) at each sampling day. Figure 1 shows the trough concentrations of the obese and non-obese groups at each time point.
In clinical practice, the therapeutic range aimed for to reduce toxicity and reduce rejection is 8-10 ng/mL during the first 3 months after transplant; 5-8 ng/mL after 3 months; 3-5 ng/mL after 12 months. For the observations crossing all the sampling time points, 72.6% (170 observations out of 234) and 70.2% (420 observations out of 598) of the observed plasma concentrations are outside the range for the obese and the non-obese patients respectively. At the specific sampling time points (i.e. day 7 and day 30 as clinically relevant time points for rejection), at day 7: 85.7% (12 observations out of 14) and 79.5% (31 observations out of 39) of the observed plasma concentrations are outside the range for the obese and the non-obese patients respectively; at day 30: 52.9% (8 observation out of 17) and 57.4% (27 observations out of 47) of the observed plasma concentrations are outside the range for the obese and nonobese patients respectively; at 6 months: 18.7% (3 observation out of 16) and 27.5% (11 observations out of 40) of the observed plasma concentrations are outside the range for the obese and non-obese patients respectively.
Figures S1-S5 in Supporting Information Appendix S1 describe the liver function test results (total bilirubin, alkaline phosphatase, gamma-glutamyl transferase, alanine transaminase and aspartate transaminase) between the obese and non-obese patients separately. Figure S6 in Appendix S2 describes the relationship between tacrolimus concentration and renal function (i.e. creatinine concentrations) in both obese and nonobese patients. Figures S7-S11 in Appendix S3 describe 
Discussion
This was a retrospective study of a large liver transplant patient cohort, examining the relationship of body size to trough concentrations when dosing is given at a set amount per kilogram total bodyweight. Exploratory analysis of the relationship between concentrations and efficacy/toxicity was also undertaken to guide future work. The major finding of this study is summarised in Figure 1 . This shows that the trough concentrations overlap at each day for the obese and the non-obese patients. This suggests that the trough concentrations between the two groups are similar regardless of body size when dosed on the recommended algorithm. Similarly, it is also observed that the number of plasma concentrations outside the therapeutic range are similar between the obese and the non-obese patients. Appendix S1 shows the relationship of liver function for the obese and the non-obese patients separately. The clinical observations mix well between the obese and the nonobese patients, suggesting that the influence of dosing on unit of patient body size appears appropriate from this retrospective audit. Appendix S2 shows that there appears to be no correlation between tacrolimus concentrations and renal toxicity in either the obese or non-obese patients, regardless of the tacrolimus concentrations (i.e. high or low). Also it shows that renal toxicity is similar between obese and non-obese patients. There appear also no correlations between the tacrolimus plasma concentrations and liver function indicators (Appendix S3). Despite our findings it has been reported frequently that tacrolimus pharmacokinetics are related to patients' body size.
10-13 Our observation is thus dissimilar as we suggest there appears no significant difference in trough concentrations of tacrolimus between groups with different body sizes when dosed on a mg/kg dosing regimen. Our speculation is that the discrepancy is explained by the fact that the random trough concentrations might not identify the body size effect appropriately, particularly as our two groups were discrete and did not examine body size as a continuous variable. More importantly, a random trough concentration may not be very representative for the complete pharmacokinetics of tacrolimus. This latter hypothesis is supported with renal transplant data with tacrolimus, showing that using the trough concentration alone to guide tacrolimus dosage adjustment can be misleading.
14-17 Trevillian et al. reported that 57.5% of kidney transplant patients in their study were over-exposed to tacrolimus despite acceptable trough concentrations in the majority, resulting in significant toxicity. Further, particularly in the renal literature a derived area under curve (AUC) measurement has been shown to be a more accurate guide than trough concentrations for tacrolimus dose adjustments.
14 BMI was the only parameter recorded in our study to describe the patient's body size. BMI might not be an appropriate pharmacological parameter to categorise the patients into non-obese and obese groups (e.g. for those with end-stage liver disease due to ascites and sarcopenia). Han et al. 18 reported in their kidney transplant study there were no statistical differences in pharmacokinetic profiles between groups with different BMI. However, significant difference in pharmacokinetics was observed between groups once specific body composition values estimated by bioelectrical impedance analysis (e.g. lean mass, fat mass and so on) were used.
Based on the present study, we propose further investigations to elicit this relationship more fully: (i) to conduct tacrolimus concentration monitoring with more after-dose blood samples and estimate the total drug exposure (i.e. AUC), subsequently to analyse the relationship between body size and AUC; (ii) to utilise distinct body composition related parameters to categorise the patients into different body size groups and then identify the body size effect; and (iii) to undertake further work in the period >30 days post-transplant.
Conclusion
This retrospective study describes the characteristics and drug exposure of a population of liver transplant patients prescribed tacrolimus. Although 30% of recipients were classified as obese, this did not appear to affect their pharmacokinetics nor toxicity profile. Specifically, tacrolimus trough concentrations after standard mg/kg dosing post liver transplant are not affected by total bodyweight. Nor does obesity affect time to the therapeutic concentrations, nor the clinical outcomes. No obvious correlations were observed between the tacrolimus plasma concentrations and the clinical outcomes. 
